Compare IQV & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | GEHC |
|---|---|---|
| Founded | 1982 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4B | 33.1B |
| IPO Year | 2013 | N/A |
| Metric | IQV | GEHC |
|---|---|---|
| Price | $221.33 | $83.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $237.59 | $86.67 |
| AVG Volume (30 Days) | 1.4M | ★ 4.0M |
| Earning Date | 02-05-2026 | 10-29-2025 |
| Dividend Yield | N/A | ★ 0.17% |
| EPS Growth | N/A | ★ 32.35 |
| EPS | ★ 7.30 | 4.83 |
| Revenue | $15,904,000,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $6.14 | $6.33 |
| Revenue Next Year | $5.35 | $4.38 |
| P/E Ratio | $30.47 | ★ $17.08 |
| Revenue Growth | ★ 3.85 | 3.51 |
| 52 Week Low | $134.65 | $57.65 |
| 52 Week High | $234.30 | $94.80 |
| Indicator | IQV | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 57.89 |
| Support Level | $220.12 | $81.74 |
| Resistance Level | $225.80 | $86.19 |
| Average True Range (ATR) | 5.19 | 2.15 |
| MACD | -1.06 | -0.24 |
| Stochastic Oscillator | 35.74 | 56.43 |
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).